Insight Molecular Diagnostics vs VolitionRx
Insight Molecular Diagnostics reported revenue of $4 million in fiscal 2025, 2.4 times VolitionRx's $2 million in fiscal 2025. Insight Molecular Diagnostics' revenue grew 115.6% in its latest year, and VolitionRx's grew 40.0%. Insight Molecular Diagnostics had an operating margin of -1260.8%, against -1258.5% at VolitionRx. Free cash flow was −$25 million at Insight Molecular Diagnostics and −$20 million at VolitionRx.
Side by side
| Insight Molecular Diagnostics | VolitionRx | |
|---|---|---|
| Latest fiscal year | FY2025, Dec 31, 2025 | FY2025, Dec 31, 2025 |
| Revenue | $4M | $2M |
| Revenue growth | 115.6% | 40.0% |
| Revenue growth a year, last 5 years | 27.9% | — |
| Gross margin | 56.7% | — |
| Operating margin | −1,260.8% | −1,258.5% |
| Net margin | −1,238.5% | −1,352.2% |
| Free cash flow | −$25M | −$20M |
| Free cash flow margin | −625.6% | −1,144.7% |
| Return on capital | — | — |
| Net debt to EBITDA | — | — |
| Dividends and buybacks | $0M | $0M |
| Change in diluted share count | 133.2% | 23.5% |
| Last close | $1.66 | $0.16 |
| P/E at the last close | — | — |
| Insider trades, last 12 months | bought $11.7 million, sold $0 | — |
| Piotroski F-score | — | 2 of 8 |
Amounts in each company's own currency, US$ unless marked (a foreign company may report in another), each company's latest fiscal year from its 10-K, or 20-F or 40-F for a foreign company. Growth rates compare with the year before; the five-year rate is the average a year. Free cash flow is cash from operations minus capital spending; return on capital is after-tax operating income over the money invested in the business; P/E is the last close over the latest earnings per share. Banks are measured differently (return on equity, efficiency ratio), so some rows apply to one company only.
Ten years
Revenue
US$ billions, fiscal years
Insight Molecular DiagnosticsVolitionRx
Operating margin
Percent of revenue
Insight Molecular DiagnosticsVolitionRx
Free cash flow
US$ billions. Cash from operations minus capital expenditure.
Insight Molecular DiagnosticsVolitionRx
Source: the companies' Form 10-K filings, from SEC EDGAR, and the last close. For information only, not investment advice: the figures describe results, not which company is the better investment. The Filing Desk is not affiliated with either company. Full figures on the Insight Molecular Diagnostics and VolitionRx pages.